An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Chronic Renal Insufficiency Clinical Trial

Official title:

A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01846468
• Other study ID #: CLHW090X2101
• Status: Completed
• Phase: Phase 1
• Start date: March 1, 2013
• Est. completion date: June 28, 2014

Study information

• Verified date: February 2017
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit ratio of several doses of the study drug to enable optimal doses to be tested in later studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 205
• Est. completion date: June 28, 2014
• Est. primary completion date: June 28, 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria: For Stage 1, 2 and 3 subjects only:

Subjects eligible for inclusion in these stages of the study have to fulfill all of the following criteria at screening:

• Healthy male and female subjects age 18 to 45 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.

• At screening, and first baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three minutes, and again (when required) after three minutes in the standing position. Sitting vital signs should be within the following ranges:

oral body temperature between 35.0-37.5 °C systolic blood pressure, 90-140 mm Hg diastolic blood pressure, 50-90 mm Hg pulse rate, 40 - 90 bpm

For Stage 4 subjects only:

• Male and female subjects, age 18 to 75 years of age included, with previously identified chronic renal insufficiency (estimated or measured GFR = 45ml/min/1.73m2, or diabetic with estimated or measured GFR = 60ml/min/1.73m2.) Diabetes can be established by the prescription and current use of anti-glycemic drugs, a random fasting glucose level of = 144mg/dl or a hemoglobin A1c of = 6.5%

• At screening, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three minutes, and again (when required) after three minutes in the standing position. Sitting vital signs should be within the following ranges:

oral body temperature between 35.0-37.5 °C systolic blood pressure, 90-179 mm Hg diastolic blood pressure, 50-100 mm Hg pulse rate, 40 - 95 bpm

Exclusion Criteria:

For Stages 1, 2 and 3, subjects fulfilling any of the following additional criteria are not eligible for inclusion in this study:

• An active history of clinically significant ECG abnormalities as determined by the Investigator, or any of the following ECG abnormalities at Screening or Baseline:

• Long QT syndrome

• QTcF > 450 msec (males; at screening)

• QTcF > 460 msec (females; at screening)

• Known history of current clinically significant arrhythmias.

• Use of phosphodiesterase-5 inhibitors, UNLESS subjects agree to discontinue use of the drug for the duration of the study.

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant

• Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during screening and at each baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine = 500 ng/ml.

• Hemoglobin levels below 11.0 g/dl at screening.

• Subjects in Stage 3 only of the study will be excluded if they have any of the following:

• A history of allergy to topical anesthetic drops

• A history of corneal disease

• A history of eye surgery within three months prior to screening

• A history of corneal surgery (including refractive surgery and corneal transplantation)

For Stage 4, subjects fulfilling any of the following additional criteria are not eligible for inclusion in this study:

• An active history of clinically significant ECG abnormalities as determined by the Investigator, or any of the following ECG abnormalities at Screening or Baseline:

• Long QT syndrome

• QTcF > 480 msec at screening

• Use of phosphodiesterase-5 inhibitors, UNLESS subjects agree to discontinue use of the drug for the duration of the study.

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant

• Significant smokers. Significant smokers who are unable to tolerate using no more than 4 cigarettes a day should be excluded

• History of right ventricular dysfunction within the last 12 months

• Hemoglobin levels below 9.0 g/dl at screening.

• Use of angiotensin converting enzyme inhibitors (ACEi), UNLESS subjects agree to either a withholding of their ACEi, or a switch to an angiotension receptor blocker, starting 5 days (or 5 half-lives which ever is longer) prior to initiation of study and extending to the end-of-study visit. Patient who withhold their ACEi for the specified duration must first consult with their primary physician to determine their suitability and safety for this temporary withholding of ACEi.

• Diuretic-dependence, i.e. unable to produce urine without diuretics, or at high risk of flash pulmonary edema without diuretics. Use of diuretics will exclude subjects UNLESS subjects agree to withhold diuretics starting the day prior to check-in and extending to discharge. Consultation of the subject with their primary physician must be used to determine their suitability and safety for temporary withholding of their diuretics.

Related Conditions & MeSH terms

• Chronic Renal Insufficiency
• Renal Insufficiency
• Renal Insufficiency, Chronic

Intervention

Drug:
• LHW090
1 mg, 12.5 mg, 100 mg capsules
• Placebo
Matching placebo capsules

Locations

Country	Name	City	State
United States	Novartis Investigative Site	Knoxville	Tennessee
United States	Novartis Investigative Site	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants (Healthy Volunteers) with reported adverse events receiving single oral dose of LHW090 as assessment of safety and tolerabiility	In this analysis AE and SAE will be reported	6 months
Primary	Number of participants (Healthy Volunteers) with reported adverse events receiving multiple oral dose of LHW090 as assessment of safety and tolerabiility	In this analysis AE and SAE will be reported	6 months
Primary	Number of participants (patients) with reported adverse events receiving single oral dose of LHW090 as assessment of safety and tolerabiility	In this analysis AE and SAE will be reported	6 months
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: observe maximum plasma concentration following LHW090 at steady state in healthy volunteers and patients	In this analysis Cmax will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: time to reach the maximum concentration after administration of LHW090 (Tmax)	In this analysis Tmax will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUClast)	In this analysis AUClast will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: area under the plasma concentration-time curve from time zero to infinity (AUCinf)	In this analysis AUCinf will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: terminal elimination half-life (T1/2)	In this analysis T1/2 will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: accumulation ratio (RACC)	In this analysis the accumulation ratio will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: apparent volume of distribution during the terminal elimination phase following extravascular administration (Vd/F)	In this analysis apparent volume of distribution during the terminal elimination phase will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in plasma: apparent system clearance from plasma following intravenous administration of iothalamate (CL/F)	In this analysis the apparent system clearance from plasma will be reported	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacokinetics of LHW090/LHV527 in urine: apparent system clearance from urine from time 0 - 24 hrs following drug administration (Ae0-24)	In this analysis the apparent system clearance by urine will be reported from 0 - 24 hrs post dose	Stage 1, 2 and 4 :0-4, 4-8, 8-12, 12-24, 24-36, 36-48 and 48 - 72 h post dose in Day 1 and Day 14; Stage 3: 0-4, 4-8, 8-12, and 12-24 h post dose
Secondary	Pharmacokinetics of LHW090/LHV527 in urine: apparent system clearance from urine from time 0 - 72 hrs following drug administration (Ae0-72h)	In this analysis the apparent system clearance by urine will be reported from 0 - 72 hrs post dose	Stage 1, 2 and 4 :0-4, 4-8, 8-12, 12-24, 24-36, 36-48 and 48 - 72 h post dose in Day 1 and Day 14; Stage 3: 0-4, 4-8, 8-12, and 12-24 h post dose
Secondary	Pharmacokinetics of LHW090/LHV527 in urine: apparent renal clearance from urine following drug administration (CLr)	In this analysis the apparent system clearance by urine will be reported	Stage 1, 2 and 4 :0-4, 4-8, 8-12, 12-24, 24-36, 36-48 and 48 - 72 h post dose in Day 1 and Day 14; Stage 3: 0-4, 4-8, 8-12, and 12-24 h post dose
Secondary	Pharmacodynamics of LHW090/LHV527 in serum: post treatment peak and mean area under the plasma concentration-time curve from time zero to 24 hour (AUC0-24h/24h) for cyclic guanosine (cGMP)	In this analysis AUC0-24/24h will be reported for single ascending dose healthy volunteers and CRI subjects	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs
Secondary	Pharmacodynamics of LHW090/LHV527 in serum: post treatment peak and mean area under the plasma concentration-time curve from time zero to 24 hour (AUC0-24h/24h) for atrial natriuretic peptide (ANP)	In this analysis AUC0-24/24h will be reported for single ascending dose healthy volunteers and CRI subjects	Within 60 min prior to dosing, post dose: +/- 5 min up to 3 hrs, +/- 10 min from =3 hrs to 24hrs, +/- 2 hrs from =24 hrs to 72hrs

External Links

•   Results for CCLHW090X2101 can be found on the Novartis Clinical Trial Results Website